Dual-monoclonal, sandwich immunoassay specific for glucose-dependent insulinotropic peptide1-42, the active form of the incretin hormone

Clinical Chemistry

Volumn 57, Issue 6, 2011, Pages 849-855

  Troutt, Jason S ^a   Siegel, Robert W ^a   Chen, Jinbiao ^a   Sloan, John H ^a   Deeg, Mark A ^a   Cao, Guoqing ^a   Konrad, Robert J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE[1-42]; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INSULIN RELEASE; MOUSE; NONHUMAN; POSTPRANDIAL STATE;

ANIMALS; ANTIBODIES, MONOCLONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GASTRIC INHIBITORY POLYPEPTIDE; HUMANS; INCRETINS; MICE;

EID: 79957780140     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.159954     Document Type: Article

References (30)

1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-7.
2. Nauck MA. Unraveling the science of incretin biology. Am J Med 2009;122:S3-10.
3. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26:2929-40. (Pubitemid 37205571)
4. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32. (Pubitemid 46048446)
5. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-17-36: a physiological incretin in man. Lancet 1987;330:1300-4. (Pubitemid 17156636)
6. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705. (Pubitemid 46048557)
7. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995;136:3585-96.
8. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000;85:3575-81.
9. McIntyre N, Holdsworth CD, Turner DS.fr New interpretation of oral glucose tolerance. Lancet 1964;284:20-1.
10. Pamir N, Lynn FC, Buchan AM, Ehses J, Hinke SA, Pospisilik JA, et al. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. Am J Physiol Endocrinol Metab 2003;284:E931-9.
11. Ehses JA, Casilla VR, Doty T, Pospisilik JA, Winter KD, Demuth HU, et al. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 2003;144:4433-45. (Pubitemid 37204843)
12. Kim SJ, Winter K, Nian C, Tsuneoka M, Koda Y, McIntosh CH. Glucose dependent insulinotropic polypeptide (GIP) stimulation of pancreatic betacell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem 2005;280:22297-307.
13. Ehses JA, Lee SS, Pederson RA, McIntosh CH. A new pathway for glucose-dependent insulinotropic polypeptide (GIP) receptor signaling: evidence for the involvement of phospholipase A2 in GIP-stimulated insulin secretion. J Biol Chem 2001;276:23667-73.
14. Kim SJ, Nian C, Widenmaier S, McIntosh CH. Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Mol Cell Biol 2008;28:1644-56.
15. 3-42 in mouse plasma by LC/ESI-MS/MS: preclinical evaluation of DPP-IV inhibitors. J Proteome Res 2009;8: 3487-96.
16. 3-42 from human plasma samples: new sensitive method to analyze physiological concentrations of peptide hormones. J Chromatogr A 2001;10:21-7.
17. Siegel RW. Antibody affinity optimization using yeast cell surface display. Methods Mol Biol 2009;504:351-83.
18. Gietz RD, Woods RA. Yeast transformation by the LiAc/SS Carrier DNA/PEG method. Methods Mol Biol 2006;313:107-20.
19. Orr-Weaver TL, Szostak JW, Rothstein RJ. Genetic applications of yeast transformation with linear and gapped plasmids. Methods Enzymol 1983; 101:228-45.
20. Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. Isolating and engineering human antibodies using yeast surface display. Nat Protoc 2006;1:755-68.
21. Feldhaus MJ. Siegel RW. Yeast display of antibody fragments: a discovery and characterization platform. J Immunol Methods 2004;290:69-80. (Pubitemid 38917131)
22. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotech 1997;15:553-7. (Pubitemid 27251573)
23. Hanes J, Plückthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci U S A 1997;94:4937-42.
24. Parmley SF, Smith GP. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 1988;73:305-18. (Pubitemid 19043263)
25. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008;60:470-512.
26. Kulkami RN. GIP: no longer the neglected incretin twin? Sci Transl Med 2010;15:2(49):49ps47.
27. Renner S, Fehlings C, Herbach N, Hofmann A, von Waldthausen DC, Kessler B, et al. Glucose intolerance and reduced proliferation of pancreatic β-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function. Diabetes 2010;59:1228-38.
28. Qiao Q, Tuomilehto J, Borch-Johnsen K. Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia 2003;46 Suppl 1:M17-21.
29. Saxena R, Hivert MF, Langenberg C, and MAGIC investigators. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010;42: 142-8.
30. Deacon CF, Plamboeck A, Rosenkilde MM, de Heer J, Holst JJ. GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations. Am J Physiol Endocrinol Metab 2006; 291:E468-75.